Pulmonary Arterial Hypertension: Triple Therapy Study

We are investigating whether a new combination of treatments, including an injectable medication, improves health outcomes for patients with pulmonary arterial hypertension. This study compares it to a standard oral treatment to see which is more effective.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Treposuvi
Tresuvi
Trisuva

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Treprostinil
Treprostinil is a substance that widens lung blood vessels to lower pulmonary blood pressure and improves breathing and ability to exercise.
Treprostinil Sodium
Treprostinil sodium is a substance that widens lung blood vessels to lower high pressure in the lungs for people with pulmonary arterial hypertension.

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

Hoppas
Hoppas
Hoppas

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Ordensklinikum Linz GmbH
Cardiology
Linz, Austria
Medical University Of Vienna
Department of Medicin II, Division of Cardiology
Vienna, Austria
University Hospital Olomouc
Cardiology
Olomouc, Czechia

Sponsor: Aop Orphan Pharmaceuticals GmbH
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.